RT Journal Article
SR Electronic
T1 Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.15.20131748
DO 10.1101/2020.06.15.20131748
A1 Jing Lu
A1 Jinju Peng
A1 Qianling Xiong
A1 Zhe Liu
A1 Huifang Lin
A1 Xiaohua Tan
A1 Min Kang
A1 Runyu Yuan
A1 Lilian Zeng
A1 Pingping Zhou
A1 Chumin Liang
A1 Lina Yi
A1 Louis du Plessis
A1 Tie Song
A1 Wenjun Ma
A1 Jiufeng Sun
A1 Oliver G Pybus
A1 Changwen Ke
YR 2020
UL http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131748.abstract
AB Background COVID-19 pandemic is underway. Some COVID-19 cases re-tested positive for SARS-CoV-2 RNA after discharge raising the public concern on their infectivity. Characterization of re-positive cases are urgently needed for designing intervention strategies.Methods Clinical data were obtained through Guangdong COVID-19 surveillance network. Neutralization antibody titre was determined using a microneutralization assay. Potential infectivity of clinical samples was evaluated after the cell inoculation. SARS-CoV-2 RNA was detected using three different RT-PCR kits and multiplex PCR with nanopore sequencing.Results Among 619 discharged COVID-19 cases, 87 were re-tested as SARS-CoV-2 positive in circumstance of social isolation. All re-positive cases had mild or moderate symptoms in initial diagnosis and a younger age distribution (mean, 30.4). Re-positive cases (n=59) exhibited similar neutralization antibodies (NAbs) titre distributions to other COVID-19 cases (n=150) parallel-tested in this study. No infective viral strain could be obtained by culture and none full-length viral genomes could be sequenced for all re-positive cases.Conclusions Re-positive SARS-CoV-2 was not caused by the secondary infection and was identified in around 14% of discharged cases. A robust Nabs response and a potential virus genome degradation were detected from nearly all re-positive cases suggesting a lower transmission risk, especially through a respiratory route.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from Guangdong Provincial Novel Coronavirus Scientific and Technological Project (2020111107001), Science and Technology Planning Project of Guangdong(2018B020207006), National Science and Technology Project(2020YFC0846800).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Medical Ethical Committee of Guangdong Provincial Center for Disease Control and Prevention. Data collection and analysis of cases were determined by the Health Commission of Guangdong province to be part of a continuing public health outbreak investigation during the emergency response and were thus considered exempt from institutional review board approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.